Pulmonx Co. (NASDAQ:LUNG) General Counsel Sells $171,015.75 in Stock

Pulmonx Co. (NASDAQ:LUNG) General Counsel David Aaron Lehman sold 22,355 shares of Pulmonx stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.65, for a total transaction of $171,015.75. Following the transaction, the general counsel now directly owns 175,496 shares in the company, valued at $1,342,544.40. This trade represents a 11.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Pulmonx Stock Down 5.5 %

Shares of NASDAQ LUNG opened at $8.19 on Thursday. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. Pulmonx Co. has a 12-month low of $5.46 and a 12-month high of $10.01. The company has a market capitalization of $325.93 million, a PE ratio of -5.69 and a beta of 0.50. The firm’s 50-day moving average is $6.93 and its two-hundred day moving average is $6.93.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.12. The company had revenue of $23.77 million during the quarter, compared to the consensus estimate of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. Equities analysts anticipate that Pulmonx Co. will post -1.55 EPS for the current fiscal year.

Analyst Ratings Changes

LUNG has been the topic of several recent analyst reports. Wells Fargo & Company decreased their price target on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Citigroup restated a “neutral” rating and issued a $7.50 price objective (down previously from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.75.

Hedge Funds Weigh In On Pulmonx

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mackenzie Financial Corp acquired a new stake in shares of Pulmonx in the fourth quarter valued at about $372,000. ProShare Advisors LLC purchased a new position in Pulmonx in the 4th quarter valued at about $72,000. Millennium Management LLC boosted its holdings in Pulmonx by 26.6% in the fourth quarter. Millennium Management LLC now owns 183,069 shares of the company’s stock valued at $1,243,000 after purchasing an additional 38,425 shares during the last quarter. Graham Capital Management L.P. raised its position in shares of Pulmonx by 73.3% in the 4th quarter. Graham Capital Management L.P. now owns 18,071 shares of the company’s stock valued at $123,000 after purchasing an additional 7,641 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its position in shares of Pulmonx by 8.9% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 392,836 shares of the company’s stock worth $2,667,000 after buying an additional 32,049 shares in the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.